Экспрессия ростовых факторов и рецепторов тирозинкиназ в клетках первичной опухоли и метастазов в надпочечники у больных почечно-клеточным раком
Мария Игоревна Волкова, Dmitry A. Khochenkov, И. В. Тимофеев et al. · 2020
Purpose. The heterogeneity of target receptors expression may cause different responses of the primary tumor and metastases of renal cell carcinoma (RCC) on tyrosine kinase inhibitors therapy. The aim of the study was to investigate expression and prognostic value of vascular endothelial growth factor (VEGFA) and fibroblast growth factor (FGF2) and their receptors VEGFR-1–3, FGFR-1–2, as well as platelet-derived growth factor receptors (PDGFR-α , -β) on the tumor cells of paired samples of the primary tumor and metastases in patients with RCC. Materials and methods. Immunohistochemical analysis with primary antibodies to VEGFA and FGF2 and receptor tyrosine kinases VEGFR-1-3, FGFR-1-2 and PDGFR-α, -β was performed on surgical specimens of kidney tumor and adrenal metastases from 21 patients with RCC. Results. Cells of RCC adrenal metastases are characterized by lower expression level of VEGFA and FGF2, as well as VEGFR-1 and VEGFR-3 compared with the primary tumor. Overexpression of growth factors and their receptors by tumor cells is associated with unfavorable morphological signs of the tumor and poor prognosis in RCC patients. Conclusions. The expression of growth factors and their tyrosine kinase receptors in the cells of the primary tumor and metastases is heterogeneous. Overexpression of the studied markers in RCC cells of any localization is associated with an unfavorable prognosis.
Cited by 0 works. doi:10.37469/0507-3758-2020-66-6-679-684
Authors
- Мария Игоревна Волкова
- Dmitry A. Khochenkov
- И. В. Тимофеев
- Anna Sergeevna Olshanskaya
- Юлия Хоченкова
- E. Sh. Solomko
- Саида Ашуба
- Vsevolod Borisovich Matveev
References
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- Expression Levels of Genes that Regulate Metastasis and Angiogenesis Correlate with Advanced Pathological Stage of Renal Cell Carcinoma
- Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma
- Preoperative Tyrosine Kinase Inhibition as an Adjunct to Debulking Nephrectomy